169 related articles for article (PubMed ID: 25362886)
1. Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?
Lopez A; Beaugerie L; Peyrin-Biroulet L
Expert Rev Clin Immunol; 2014 Dec; 10(12):1563-5. PubMed ID: 25362886
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease.
Lopez A; Mounier M; Bouvier AM; Carrat F; Maynadié M; Beaugerie L; Peyrin-Biroulet L;
Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1324-9. PubMed ID: 24582568
[TBL] [Abstract][Full Text] [Related]
3. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
McKenna MR; Stobaugh DJ; Deepak P
J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
[TBL] [Abstract][Full Text] [Related]
4. The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders.
Friedman AB; Sparrow MP; Gibson PR
Int J Rheum Dis; 2014 Feb; 17(2):132-41. PubMed ID: 24618304
[TBL] [Abstract][Full Text] [Related]
5. Thiopurines during pregnancy in inflammatory bowel disease: is there a risk for the (unborn) child?
de Boer NK; de Meij T; van Bodegraven AA
Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):669-71. PubMed ID: 24134152
[No Abstract] [Full Text] [Related]
6. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
Peyrin-Biroulet L; Khosrotehrani K; Carrat F; Bouvier AM; Chevaux JB; Simon T; Carbonnel F; Colombel JF; Dupas JL; Godeberge P; Hugot JP; Lémann M; Nahon S; Sabaté JM; Tucat G; Beaugerie L;
Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
[TBL] [Abstract][Full Text] [Related]
7. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease.
Singh H; Nugent Z; Demers AA; Bernstein CN
Gastroenterology; 2011 Nov; 141(5):1612-20. PubMed ID: 21806945
[TBL] [Abstract][Full Text] [Related]
9. Do children with IBD really respond better than adults to thiopurines?
Goodhand JR; Tshuma N; Rao A; Kotta S; Wahed M; Croft NM; Sanderson IR; Epstein J; Rampton DS
J Pediatr Gastroenterol Nutr; 2011 Jun; 52(6):702-7. PubMed ID: 21593643
[TBL] [Abstract][Full Text] [Related]
10. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease.
Smith MA; Irving PM; Marinaki AM; Sanderson JD
Aliment Pharmacol Ther; 2010 Jul; 32(2):119-30. PubMed ID: 20412066
[TBL] [Abstract][Full Text] [Related]
11. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.
Beaugerie L; Brousse N; Bouvier AM; Colombel JF; Lémann M; Cosnes J; Hébuterne X; Cortot A; Bouhnik Y; Gendre JP; Simon T; Maynadié M; Hermine O; Faivre J; Carrat F;
Lancet; 2009 Nov; 374(9701):1617-25. PubMed ID: 19837455
[TBL] [Abstract][Full Text] [Related]
12. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.
Marzano AV; Borghi A; Meroni PL; Crosti C; Cugno M
Autoimmunity; 2014 May; 47(3):146-53. PubMed ID: 24437626
[TBL] [Abstract][Full Text] [Related]
13. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meeting.
van Asseldonk DP; Sanderson J; de Boer NK; Sparrow MP; Lémann M; Ansari A; Almer SH; Florin TH; Gearry RB; Mulder CJ; Mantzaris G; van Bodegraven AA;
Dig Liver Dis; 2011 Apr; 43(4):270-6. PubMed ID: 20934926
[TBL] [Abstract][Full Text] [Related]
14. Risk of Myeloid Neoplasms in Inflammatory Bowel Disease Patients Is Linked to Exposure to Thiopurines and Not With Tumor Necrosis Factor-alpha Inhibitors.
Deepak P; Stobaugh DJ
Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1857-8. PubMed ID: 25158928
[No Abstract] [Full Text] [Related]
15. Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place.
van Hoeve K; Vermeire S
Paediatr Drugs; 2020 Oct; 22(5):449-461. PubMed ID: 32797366
[TBL] [Abstract][Full Text] [Related]
16. On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance.
Van Asseldonk DP; de Boer NK; Peters GJ; Veldkamp AI; Mulder CJ; Van Bodegraven AA
Curr Drug Metab; 2009 Nov; 10(9):981-97. PubMed ID: 20214590
[TBL] [Abstract][Full Text] [Related]
17. Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: A systematic review and meta-analysis.
Huang SZ; Liu ZC; Liao WX; Wei JX; Huang XW; Yang C; Xia YH; Li L; Ye C; Dai SX
J Gastroenterol Hepatol; 2019 Mar; 34(3):507-516. PubMed ID: 30393891
[TBL] [Abstract][Full Text] [Related]
18. Cancer and immunomodulators in inflammatory bowel diseases.
Biancone L; Onali S; Petruzziello C; Calabrese E; Pallone F
Inflamm Bowel Dis; 2015 Mar; 21(3):674-98. PubMed ID: 25545375
[TBL] [Abstract][Full Text] [Related]
19. A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients.
Biemans VBC; Savelkoul E; Gabriëls RY; Simsek M; Dijkstra G; Pierik MJ; West RL; de Boer NKH; Hoentjen F
Aliment Pharmacol Ther; 2020 Jun; 51(11):1076-1086. PubMed ID: 32339331
[TBL] [Abstract][Full Text] [Related]
20. Hepatotoxicity of agents used in the management of inflammatory bowel disease.
Khokhar OS; Lewis JH
Dig Dis; 2010; 28(3):508-18. PubMed ID: 20926880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
